Physician profile
Angelo Constantino
NPI 1669479283
$16,107.98
in general payments reported to CMS, 2019-2025
46 companies · $1,181 in 2025
The $1,181 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,619 · 2020: $2,348 · 2021: $3,205 · 2022: $2,805 · 2023: $1,937 · 2024: $2,013 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,131.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,150.78 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $1,713.72 | 2019-2025 | Wegovy |
| Amgen INC. | $1,522.11 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $1,496.00 | 2019-2025 | Ubrelvy, Vraylar, Linzess |
| Glaxosmithkline, LLC. | $1,204.73 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,183.97 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $888.57 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $775.30 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $577.00 | 2019-2025 | Verquvo, Belsomra |
| Amarin Pharma, INC. | $390.57 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $371.93 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $370.80 | 2019-2024 | Camzyos, Eliquis |
| Astellas Pharma US INC | $347.28 | 2019-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $320.40 | 2019-2023 | |
| Daiichi Sankyo INC. | $309.91 | 2019-2024 | Injectafer, Vanflyta |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelo Constantino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.